688677.SHG Qingdao NovelBeam Technology Co. Ltd. A
- Market cap
- CNY 6.42B
- P/E
- 40.3x
- P/B
- 4.58x
- ROE
- 11.4%
- Dividend yield
- 1.15%
- Fundamental score
- -
Ratios use the latest price and the current fiscal year annualized from 3 quarters up to Sep 2026.
Is 688677.SHG undervalued?
Graham number688677.SHG trades 186.2% above its Graham number.
Graham number = √(22.5 × EPS × book value per share): the most a defensive investor should pay according to Benjamin Graham. An estimate, not a recommendation to buy or sell. How is it calculated?
Qingdao NovelBeam Technology Co. Ltd. A fundamental analysis
No fundamental analysis for Qingdao NovelBeam Technology Co. Ltd. A yet.
Qingdao NovelBeam Technology Co. Ltd. A stock price
Prices on the chart can differ slightly from the closing prices StockSummer uses for its ratios.
About Qingdao NovelBeam Technology Co. Ltd. A
Qingdao NovelBeam Technology Co.,Ltd. engages in the research and development, production, sales, and service of medical endoscopic instruments and optical products in China and internationally. The company offers IV endoscopic surgery workstation, camera system, LED cold light source, and laparoscope; OV clinic and surgery workstation; and optics products. It also provides endoscope, light source, camera system, surgical imaging system, endoscopic system, and operation room…
Full company profileQingdao NovelBeam Technology Co. Ltd. A financial statements
2026 annualized: Fiscal year 2026 is not finished. Income statement and cash flow are annualized from 3 quarters up to Sep 30, 2026, the balance sheet is the latest quarter. Figures change when the annual report is published.
Qingdao NovelBeam Technology Co. Ltd. A annual financial statements (CNY; K = thousand, M = million, B = billion, T = trillion)
| Item | 2016 | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | 2026 Anlz |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Income Statement | |||||||||||
| Revenue | 139M | 181M | 201M | 253M | 275M | 310M | 477M | 471M | 443M | 603M | 643M |
| Gross Profit | 76.4M | 105M | 113M | 146M | 173M | 193M | 305M | 294M | 280M | 603M | 403M |
| Operating Income | 35.4M | 57.3M | 63.1M | 82.6M | 111M | 134M | 206M | 161M | 153M | 190M | 198M |
| EBITDA | 41.6M | 65.2M | 68.7M | 91.4M | 122M | 143M | 220M | 184M | 179M | 217M | 167M |
| Net Income | 32.8M | 51.1M | 54.6M | 71.9M | 96.4M | 118M | 183M | 146M | 135M | 172M | 150M |
| EPS | 0.99 | 0.54 | 0.56 | 0.77 | 1.06 | 1.01 | 1.50 | 1.20 | 1.12 | 1.44 | 1.25 |
| Balance Sheet | |||||||||||
| Total Assets | 211M | 231M | 273M | 330M | 417M | 1.18B | 1.39B | 1.39B | 1.46B | 1.63B | 1.68B |
| Total Liabilities | 69.0M | 37.2M | 43.5M | 105M | 97.6M | 87.0M | 171M | 102M | 155M | 290M | 370M |
| Shareholders' Equity | 142M | 194M | 224M | 220M | 315M | 1.09B | 1.22B | 1.29B | 1.30B | 1.35B | 1.32B |
| Cash & Short-term Investments | 38.3M | 57.0M | 49.8M | 57.8M | 82.8M | 723M | 636M | 631M | 524M | 588M | 500M |
| Total Debt | 49.0M | 5.00M | 10.0M | 40.0M | 49.4M | 22.5M | 19.2M | 5.93M | 1.45M | - | - |
| Cash Flow | |||||||||||
| Operating Cash Flow | 36.6M | 66.1M | 48.3M | 83.5M | 115M | 104M | 104M | 158M | 112M | 160M | - |
| Capital Expenditure | 9.96M | 7.51M | 34.1M | 40.6M | 68.6M | 100M | 102M | 56.0M | 76.3M | 26.7M | 97.1M |
| Free Cash Flow | 26.7M | 58.6M | 14.3M | 42.9M | 46.2M | 3.89M | 2.70M | 102M | 36.0M | 133M | 20.8M |
| Ratios | |||||||||||
| ROE | 23.0% | 26.3% | 24.4% | 32.7% | 30.6% | 10.8% | 15.0% | 11.3% | 10.4% | 12.7% | 11.4% |
| ROA | 15.5% | 22.1% | 20.0% | 21.8% | 23.1% | 10.0% | 13.1% | 10.4% | 9.3% | 10.5% | 8.9% |
| Net Profit Margin | 23.5% | 28.2% | 27.2% | 28.4% | 35.0% | 38.0% | 38.3% | 31.0% | 30.6% | 28.5% | 23.4% |
| Debt to Equity | 0.34x | 0.03x | 0.04x | 0.18x | 0.16x | 0.02x | 0.02x | 0.00x | 0.00x | - | - |
What these items mean
- Revenue
- Total sales of goods and services in the period.
- Gross Profit
- Revenue minus the direct cost of producing what was sold.
- Operating Income
- Profit from the core business after operating expenses.
- EBITDA
- Earnings before interest, taxes, depreciation and amortization.
- Net Income
- Profit left for shareholders after all expenses, interest and taxes.
- EPS
- Net income divided by shares outstanding.
- Total Assets
- Everything the company owns.
- Total Liabilities
- Everything the company owes.
- Shareholders' Equity
- Assets minus liabilities: the book value that belongs to shareholders.
- Cash & Short-term Investments
- Cash and investments that can be turned into cash quickly.
- Total Debt
- Short and long-term borrowings.
- Operating Cash Flow
- Cash generated by the core business.
- Capital Expenditure
- Cash spent on property, plant and equipment.
- Free Cash Flow
- Operating cash flow minus capital expenditure: cash left for dividends, buybacks or debt repayment.
- ROE
- Return on equity: net income divided by shareholders' equity.
- ROA
- Return on assets: net income divided by total assets.
- Net Profit Margin
- Net income as a share of revenue.
- Debt to Equity
- Total debt divided by shareholders' equity.
Qingdao NovelBeam Technology Co. Ltd. A dividends
- Dividend yield
- 1.15%
- Forward dividend
- 0.60 CNY
- Payout ratio
- 43.2%
- Ex-dividend date
- Jun 10, 2026
| Fiscal year | Dividends paid | Per share | Payout ratio |
|---|---|---|---|
| 2025 | CNY 74.1M | 0.62 | 43.2% |
| 2024 | CNY 66.7M | 0.55 | 49.3% |
| 2023 | CNY 69.3M | 0.57 | 47.6% |
| 2022 | CNY 35.7M | 0.29 | 19.5% |
| 2021 | CNY 34.8M | 0.30 | 29.6% |
| 2020 | CNY 1.89M | 0.02 | 2.0% |
| 2019 | CNY 33.7M | 0.36 | 46.8% |
| 2018 | 34.3M | 0.35 | 62.9% |
| 2017 | 2.02M | 0.02 | 3.9% |
From the cash flow statement: dividends paid in the fiscal year, divided by that year's shares outstanding. Payout ratio = dividends paid / net income.
Last stock split: 1.4:1 on Jun 14, 2023.
Who owns Qingdao NovelBeam Technology Co. Ltd. A
- Insiders 41.58%
- Institutions 11.05%
- Public & others 47.36%
- Shares outstanding 120M
- Free float 54.4M
Qingdao NovelBeam Technology Co. Ltd. A company profile
- Company name
- Qingdao NovelBeam Technology Co. Ltd. A
- Ticker
- 688677.SHG
- ISIN
- CNE100005410
- Exchange
- Shanghai Stock Exchange
- Sector
- Healthcare
- Industry
- Health Care Equipment & Supplies
- Employees
- 1,070
- Fiscal year end
- December
- Address
- No.100 Keyuanweisi Road, Qingdao, China, 266100
- Phone
- 86 532 8870 6015
- Website
- novelbeam.com
About Qingdao NovelBeam Technology Co. Ltd. A
Qingdao NovelBeam Technology Co.,Ltd. engages in the research and development, production, sales, and service of medical endoscopic instruments and optical products in China and internationally. The company offers IV endoscopic surgery workstation, camera system, LED cold light source, and laparoscope; OV clinic and surgery workstation; and optics products. It also provides endoscope, light source, camera system, surgical imaging system, endoscopic system, and operation room visualization solutions; optical components, optomechanical modules, and integrated systems; and technical support and value-added services. Its products are used in clinical surgery, analytical diagnostics, industrial applications, and lasers. The company was founded in 2003 and is headquartered in Qingdao, China.
Qingdao NovelBeam Technology Co. Ltd. A management
6- Mr. Yao ZhengGM & Director · born 1974
- Mr. Fanghua WangDeputy GM, CFO & Board Secretary · born 1968
- Ms. Min MaDirector of Operations Management Center · born 1973
- Mr. Changming GuDeputy GM, Technical Director & Director · born 1972
- Mr. Rongzhuang MaoGeneral Manager of OMEK Healthcare · born 1979
- Mingming ChenAccounting Supervisor